Purpose: The delivery quality assurance (DQA) of intensity-modulated radiotherapy (IMRT) plans is a prerequisite for ensuring patient treatments. This work investigated the clinical usefulness of a new DQA system, Dosimetry Check™(DC), on TomoTherapy ® -based helical IMRT plans.
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| INTRODUCTION
Modern radiotherapy has become more complicated in its quest to deliver a highly conformal dose to a defined target volume, while sparing organs at risk near the target volume. The TomoTherapy ® (Accuray, Sunnyvale, CA, USA) is one of the modern radiotherapy systems allowing a continuous dose delivery in a helical fashion around the anatomical site to be treated. The quality assurance (QA) of dose delivery using TomoTherapy ® is a prerequisite for ensuring patient treatments.
For TomoTherapy ® -based intensity-modulated radiotherapy (IMRT), the current delivery quality assurance (DQA) process consists of comparing measured versus calculated doses in a phantom using an ionization chamber and a film 1,2 or using detector array devices. [3] [4] [5] [6] These devices have generally provided such accurate DQA results in terms of low absolute dose difference or high gamma pass rate. However, these DQA processes are also time-consuming and laborious to TomoTherapy ® users since a separate DQA plan corresponding to each treatment plan needs to be created. Moreover, heavy devices are required on the treatment couch of the TomoTherapy ® system to perform the DQA measurements. It must be underlined that the DQAs performed with the above-mentioned methods allow the dose comparison between the measurement and calculation only in the small region or the plane, where the measurement tools (i.e., the ionization chamber, film, detector array, etc.) are positioned, and require much work in cases where the volume to be treated extends beyond their physical dimensions. Therefore, with the current TomoTherapy ® DQA modalities, it is hard to identify the region accurately inside the patient body where non-negligible dose difference between the measurement and calculation is present.
Recently, various new systems have been commercially released for DQA of patient treatment plans using modern radiotherapy modalities. 5, 7 These systems use log-files of the beam irradiation or measured beam fluence to reconstruct the dose distribution on the CT images of patients, thereby reconstructing the dose to the target and surrounding normal structures. These systems make the DQA analysis available not only in a point dose and two-dimensional (2D) planar dose distribution but also in three-dimensional (3D) volumetric dose distribution inside the patient body. Therefore, users can compare the dose distribution between the measurement and calculation in more detail compared with the traditional DQA methods. 
based helical IMRT plans
The patient-specific DQA test with DC was performed for 15 different TomoTherapy ® -based helical treatment plans, which were randomly selected from our institution's patient list. Seven treatment plans were delivered on the TomoTherapy ® HD unit and other eight treatment plans were delivered on the TomoTherapy ® Hi-ART unit. The treatment sites of these clinical plans were prostate, brain, head and neck, lung, abdomen and spine. Most of the treatment plans were generated using the 2.5 cm field width except for one abdomen treatment plan, which was created using the 5.0 cm field width.
In the TomoTherapy ® treatment machine, a couch position was set to a height of 400 mm and each plan was delivered using QA- The DC-reconstructed and TomoTherapy ® TPS-calculated dose distributions were compared at a point dose as well as in 1D, 2D, and 3D methods. The 1D dose profile was compared in x-, y-, and z-axes defined at the reference point. The 2D planar dose was compared in transverse, coronal and sagittal planes defined at the reference point using a gamma analysis method. The 3D volumetric comparison was performed using 3D gamma pass analysis. Both the 2D and 3D gamma pass analysis were performed using a 3%/3 mm dose difference/distance to agreement criteria 11 as recommended by AAPM TG-148 Report. respectively. The chamber was positioned 5 mm below the center of the cheese phantom and polarized with −300 V using the TomoElectrometer. The EBT3 film was positioned in coronal or sagittal direction at the middle of the cheese phantom. After the cheese phantom was irradiated with the DQA plan, the measured point dose and 2D planar dose distribution were compared with the calculated ones using the TomoTherapy ® DQA workstation.
| RESULTS

3.A | Dose delivery verification
In Table 1 were prostate, head and neck, lung and L-spine, the absolute dose difference was less than ±3% and the 2D and 3D gamma pass rates with the 3%/3 mm gamma criteria were greater than 95% with both DQA methods. However, for the abdomen treatment plan (Patient No. 7), it was shown that the absolute dose difference was greater than 3% and the gamma pass rate with the 3%/3 mm gamma criteria was less than 95% with DC. When using the cheese phantom, on the other hand, the DQA result for the same treatment plan passed our institution's tolerance, i.e., the absolute dose difference is less than 3% and the gamma pass rate with the 3%/3 mm gamma criteria is greater than 95% in 2D planar evaluation. The clinical availability of DC has been investigated by various research groups for DQA of linear accelerator (LINAC) and TomoTherapy ® -based IMRT plans. [13] [14] [15] [16] [17] [18] These studies reported that the DC-calculated 3D volumetric gamma pass rates for the patientspecific DQAs were greater than 90%. Mezzenga et al. 16 reported T A B L E 2 Summary of DQA results of the 15 clinical TomoTherapy ® treatment plans using the Dosimetry Check™ and cheese phantom method. The P-value for the absolute dose difference determined by the two different DQA methods was calculated using Wilcoxon signedrank test. rates greater than 95% with the 3%/3 mm gamma criteria both in 2D planar and 3D volumetric evaluations using a 5.0 mm grid size.
| DISCUSSION
We analyzed the gamma pass rates not only in 3D volume but also In this work, since DC installed in our institution was primarily used for the DQA before the patient treatment, it was only commissioned on the pretreatment dosimetry mode. As mentioned by Mezzenga et al. 16 and Gimeno et al., 18 DC also can be used on the 
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